Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Gabriel C. Caponetti, Bhavana J Dave, Anamarija M. Perry, Lynette M Smith, Smrati Jain, Paul N. Meyer, Martin Bast, Philip Jay Bierman, Robert G Bociek, Julie Marie Vose, James Olen Armitage, Patricia Aoun, Kai Fu, Timothy Charles Greiner, Wing C. Chan, Warren G. Sanger, Dennis D. Weisenburger

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

Original languageEnglish (US)
Pages (from-to)3082-3089
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Chromosome Aberrations
Disease-Free Survival
Cytogenetic Analysis
Fluorescence In Situ Hybridization
Lymphoma
Genes
Therapeutics

Keywords

  • BCL2
  • BCL6
  • Diffuse large B-cell lymphoma
  • MYC

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. / Caponetti, Gabriel C.; Dave, Bhavana J; Perry, Anamarija M.; Smith, Lynette M; Jain, Smrati; Meyer, Paul N.; Bast, Martin; Bierman, Philip Jay; Bociek, Robert G; Vose, Julie Marie; Armitage, James Olen; Aoun, Patricia; Fu, Kai; Greiner, Timothy Charles; Chan, Wing C.; Sanger, Warren G.; Weisenburger, Dennis D.

In: Leukemia and Lymphoma, Vol. 56, No. 11, 02.11.2015, p. 3082-3089.

Research output: Contribution to journalArticle

Caponetti, Gabriel C. ; Dave, Bhavana J ; Perry, Anamarija M. ; Smith, Lynette M ; Jain, Smrati ; Meyer, Paul N. ; Bast, Martin ; Bierman, Philip Jay ; Bociek, Robert G ; Vose, Julie Marie ; Armitage, James Olen ; Aoun, Patricia ; Fu, Kai ; Greiner, Timothy Charles ; Chan, Wing C. ; Sanger, Warren G. ; Weisenburger, Dennis D. / Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 11. pp. 3082-3089.
@article{8fbb7d25b8454385aecc04a0cb67f950,
title = "Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome",
abstract = "In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84{\%}) were classified as MYC-, 17 (8{\%}) were MYC+/BCL2-/BCL6-, and 16 (8{\%}) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.",
keywords = "BCL2, BCL6, Diffuse large B-cell lymphoma, MYC",
author = "Caponetti, {Gabriel C.} and Dave, {Bhavana J} and Perry, {Anamarija M.} and Smith, {Lynette M} and Smrati Jain and Meyer, {Paul N.} and Martin Bast and Bierman, {Philip Jay} and Bociek, {Robert G} and Vose, {Julie Marie} and Armitage, {James Olen} and Patricia Aoun and Kai Fu and Greiner, {Timothy Charles} and Chan, {Wing C.} and Sanger, {Warren G.} and Weisenburger, {Dennis D.}",
year = "2015",
month = "11",
day = "2",
doi = "10.3109/10428194.2015.1034699",
language = "English (US)",
volume = "56",
pages = "3082--3089",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

AU - Caponetti, Gabriel C.

AU - Dave, Bhavana J

AU - Perry, Anamarija M.

AU - Smith, Lynette M

AU - Jain, Smrati

AU - Meyer, Paul N.

AU - Bast, Martin

AU - Bierman, Philip Jay

AU - Bociek, Robert G

AU - Vose, Julie Marie

AU - Armitage, James Olen

AU - Aoun, Patricia

AU - Fu, Kai

AU - Greiner, Timothy Charles

AU - Chan, Wing C.

AU - Sanger, Warren G.

AU - Weisenburger, Dennis D.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

AB - In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

KW - BCL2

KW - BCL6

KW - Diffuse large B-cell lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84947744551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947744551&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1034699

DO - 10.3109/10428194.2015.1034699

M3 - Article

C2 - 25827211

AN - SCOPUS:84947744551

VL - 56

SP - 3082

EP - 3089

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -